metaEvidence - overview

benefit
(statisticaly significant)

benefit (nominaly significant, not statitically demonstrated)

not significant

harm statitically significant

harm not significant

low certainty due to bias


			deaths (OS)
mGC or mGEJC - L1 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - PDL1 positive
versus placebo plus SoC
	pembrolizumab alone vs. placebo plus SoC	1
	pembrolizumab plus SoC vs. placebo plus SoC	2
versus Standard of Care (SoC)
	pembrolizumab alone vs. Standard of Care (SoC)	1